Otoimmün Myastenia Gravis
Özet
Myastenia gravis, nöromüsküler kavşaktaki postsinaptik membranı hedef alan otoantikorların neden olduğu, kas güçsüzlüğü ile karakterize bir hastalıktır. En belirgin klinik bulgular pitoz ve diplopi gibi oküler belirtiler olup, hastalık jeneralize bir hal alarak solunum kaslarını da etkileyebilmektedir. Tanı, klinik tabloya ek olarak serolojik antikor testleri ve elektrofizyolojik incelemelerle desteklenir; tedavi yaklaşımı ise semptomatik ilaçlar, immünosupresyon ve uygun vakalarda timektomiyi içerir. Hastalık, patofizyolojik ve klinik özelliklerine göre farklı alt gruplara ayrılarak kişiselleştirilmiş tedavi süreçlerinin yönetilmesine olanak tanır.
Myasthenia gravis is an autoimmune disorder characterized by muscle weakness, caused by autoantibodies targeting the postsynaptic membrane at the neuromuscular junction. The most prominent clinical findings include ocular symptoms such as ptosis and diplopia, though the disease can progress to a generalized form affecting respiratory muscles. Diagnosis is supported by clinical presentation alongside serological antibody tests and electrophysiological studies, while treatment approaches include symptomatic medication, immunosuppression, and thymectomy in selected cases. The disease is categorized into different subtypes based on its pathophysiological and clinical characteristics, enabling the management of personalized treatment processes.
Referanslar
Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JGM. Myasthenia gravis. Nat Rev Dis Primers. 2019;(30):5.
Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016;375(26):2570-2581.
Kerty, E., Elsais, A., Argov, Z., Evoli, A. & Gilhus, N. E. EFNS/ENS Guidelines for the treatment of ocular myasthenia. Eur. J. Neurol. 2014;21, 687–693.
Gilhus, N. E. & Verschuuren, J. J. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14, 1023–1036.
Hong, Y. et al. Multiple antibody detection in ‘seronegative’ myasthenia gravis patients. Eur. J. Neurol. 2017;24, 844–850.
Andersen, J. B., Gilhus, N. E. & Sanders, D. B. Factors affecting outcome in myasthenia gravis. Muscle Nerve 2016;54, 1041–1049.
Silvestri NJ, Barohn RJ, Wolfe GI. Acquired Disorders of the Neuromuscular Junction. Swaiman KF, Ashwal S, Ferriero DM, et al (eds). Swaiman’s Pediatric Neurology. 6. Ed. Edinburgh: Elsevier; 2018. p.2462-2476.
Punga, A. R. & Punga, T. Circulating microRNAs as potential biomarkers in myasthenia gravis patients. Ann. NY Acad. Sci. 2018;1412:33–40.
Gilhus, N. E., Romi, F., Hong, Y. & Skeie, G. O. Myasthenia gravis and infectious disease. J. Neurol. 2018;265:1251–1258.
Kao, J. C., Brickshawana, A. & Liewluck, T. Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors. Curr. Neurol. Neurosci. Rep. 2018;18, 63.
Tuzun, E. & Christadoss, P. Complement associated pathogenic mechanisms in myasthenia gravis. Autoimmun. Rev. 2013;12:904–911.
Kordas, G., Lagoumintzis, G., Sideris, S., Poulas, K. & Tzartos, S. J. Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients. PLOS ONE 10, e0117673 (2015).
Zisimopoulou, P., Brenner, T., Trakas, N. & Tzartos, S. J. Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmun. Rev. 2013;12:924–930.
Messeant, J. et al. MuSK frizzled-like domain is critical for mammalian neuromuscular junction formation and maintenance. J. Neurosci. 2015;35:4926–4941.
Koneczny, I. et al. IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients. J. Autoimmun. 2017;77:104–115.
Zisimopoulou, P. et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J. Autoimmun. 2014;52:139–145.
Gasperi, C. et al. Anti-agrin autoantibodies in myasthenia gravis. Neurology 2014;82;1976–1983.
Cossins, J. et al. in Myasthenia Gravis and Related Disorders II: 12th International Conference Vol. 1275 (eds Wolfe, G. I., Meriggioli, M. N., Ciafaloni, E. & Ruff, R. L.) 123–128 (Wiley, 2012).
Romi, F. et al. Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis. J. Neurol. 2012;259:1312–1316.
Romi, F., Hong, Y. & Gilhus, N. E. Pathophysiology and immunological profile of myasthenia gravis and its subgroups. Curr. Opin. Immunol. 2017;49:9–13.
Gallardo, E. et al. Cortactin autoantibodies in myasthenia gravis. Autoimmun. Rev. 2014;13:1003–1007.
Romi F, Skeie GO, Gilhus NE, Aarli JA. Striational antibodies in myasthenia gravis: reactivity and possible clinical sig- nificance. Arch Neurol 2005;62:442-6.
Gasperi C, Melms A, Schoser B, et al. Anti-agrin autoantibodies in myasthenia gravis. Neurology 2014;82:1976-83.
Gilhus NE, Skeie GO, Romi F, Lazari- dis K, Zisimopoulou P, Tzartos S. Myas- thenia gravis — autoantibody character- istics and their implications for therapy. Nat Rev Neurol 2016;12:259-68.
Suzuki S, Baba A, Kaida K, et al. Car- diac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies. Eur J Neurol 2014;21:223-30.
Anlar B, Şenbil N, Köse G, Değerliyurt A. Serological follow-up in juvenile myasthenia: clinical and acetylcholine receptor antibody status of patients followed for at least 2 years. Neuromuscul Disord 2005;15:355-7.
Castro D, Derisavifard S, Anderson M, Greene M, Iannaccone S. Juvenile myasthenia gravis: A twenty-year experience. J Clin Neuromusc Dis 2013;14:95-102.
Peragallo JH. Pediatric Myasthenia Gravis. Seminars in Pediatric Neurology. 2017;24(2):116-121.
Zisimopoulou P, Evangelakou P, Tzartos J, Lazaridis K, Zouvelou V, Mantegazza R, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 2014;52:139-45.
Gilhus, N. E. et al. Myasthenia gravis - autoantibody characteristics and their implications for therapy. Nat. Rev. Neurol. 2016;12:259–268.
Bonanno, S. et al. Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study. Sage Open Med. 2018;6, 2050312118819013.
Sathasivam, S. Current and emerging treatments for the management of myasthenia gravis. Ther. Clin. Risk Manag. 2011;7:313–323.
Tandan, R., Hehir, M. K., Waheed, W. & Howard, D. B. Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve 2017;56:185–196.
Mantegazza, R., Bonanno, S., Camera, G. & Antozzi, C. Current and emerging therapies for the treatment of myasthenia gravis. Neuropsychiatr. Dis. Treat 2011;7:151–160.
